Reviva Pharmaceuticals Engages with Experts in Upcoming Webinar
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is poised to create waves in the pharmaceutical industry with a key opinion leader (KOL) webinar on horizon, where they plan to showcase their innovative approaches in addressing profound medical needs. The company, recognized for its commitment to developing advanced therapies, will be represented by Laxminarayan Bhat, PhD, the Founder and CEO, during this important gathering.
What to Expect from the Webinar
Scheduled for 11:00 AM ET, this webinar promises to be an insightful event featuring a fireside chat with Dr. Bhat, accompanied by notable KOLs, including Dr. Larry Ereshefsky and Dr. Mark Opler. The discussions are set to delve into critical topics concerning the treatment landscape for schizophrenia, highlighting Reviva’s lead drug candidate, brilaroxazine. This medication has the potential to illuminate new avenues for treating this complex condition.
Expert Insights
Dr. Ereshefsky, with his extensive background in CNS consulting and clinical sciences, will provide valuable perspectives on the current challenges and opportunities within this field. Likewise, Dr. Opler, known for his expertise in research and clinical initiatives, will contribute to discussions around how brilaroxazine may affect those suffering from schizophrenia. As moderating host, James Molloy from A.G.P./Alliance Global Partners will ensure an engaging dialogue that benefits attendees.
Reviva’s Commitment to Innovation
At the heart of Reviva's mission is addressing unmet medical needs. The company focuses on developing therapies aimed at improving the lives of those affected by CNS disorders, inflammatory conditions, and cardiometabolic diseases. This commitment to innovation shines through with their drug candidates, with brilaroxazine being a standout option that presents new hope for individuals struggling with the symptoms of schizophrenia.
Pipeline Overview
Reviva’s current pipeline also includes another promising candidate, RP1208. Both of these drugs are new chemical entities developed in-house, showcasing Reviva's dedication to pioneering medical research. Furthermore, Reviva has secured composition of matter patents for both drug candidates across the United States, Europe, and several other countries, underscoring its strong position in the pharmaceutical market.
Connecting with Reviva
For those interested in gaining insights into Reviva's groundbreaking work, registering for the webinar is a valuable opportunity. Not only does this event serve as a platform for learning, but it also fosters connections between experts and the community. A replay of the webinar will be accessible on Reviva’s website for further exploration after the event.
Corporate & Investor Relations
If you have any inquiries or need additional information about Reviva Pharmaceuticals, you can contact them directly. Laxminarayan Bhat, PhD, can be reached through Reviva's official website, ensuring that stakeholders and interested parties can stay informed about developments and future events.
Frequently Asked Questions
What is the focus of Reviva Pharmaceuticals?
Reviva is dedicated to developing therapeutics aimed at addressing unmet medical needs in CNS, inflammatory, and cardiometabolic diseases.
Who will participate in the upcoming webinar?
The webinar will feature Reviva's CEO, Laxminarayan Bhat, PhD, and KOLs including Dr. Ereshefsky and Dr. Opler.
What is brilaroxazine?
Brilaroxazine is Reviva’s lead drug candidate developed for treating symptoms of schizophrenia, representing a new approach in therapy.
How can I register for the webinar?
Interested participants can register for the webinar through Reviva’s communication channels, and a replay will be available afterward.
What is the significance of Reviva's pipeline?
Reviva's pipeline signifies its commitment to innovation, focusing on bringing forward drugs that potentially change lives and treatments in various medical fields.
